Clinical Trial Update: Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib-s-malate plus erlotinib in patients with previously treated metastatic non-small cell lung cancer has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2019-05-16